OncoMatch

OncoMatch/Clinical Trials/NCT04536805

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

Is NCT04536805 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Metformin for prostate cancer.

Phase 1/2RecruitingInstitut Cancerologie de l'OuestNCT04536805Data as of Jun 2026Location: France

Treatment: MetforminThis phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Metformin

Cancer type

Prostate Cancer

Performance status

WHO 0–1

Demographics

Male only

Prior therapy

Must have received: external radiotherapy — prostate lodge

Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy

Must have received: hormone therapy

Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy

Must have received: radical prostatectomy

for prostatic adenocarcinoma previously treated by radical prostatectomy

Cannot have received: metformin

Treatment with metformin in the last 3 months prior to inclusion

Cannot have received: investigational drug

Treatment with any investigational drug or participation in a clinical trial within 30 days prior to inclusion

Lab requirements

Kidney function

Creatinine clearance >= 45 mL/min

Creatinine clearance < 45 mL/min [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04536805 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior metformin, investigational drug disqualifies patients from enrollment.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify